Enterprise Value
121.2M
Cash
103M
Avg Qtr Burn
-15.1M
Short % of Float
1.29%
Insider Ownership
41.87%
Institutional Own.
30.23%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PI-2620 Details Neurological disorder, Alzheimer's disease | Phase 3 Data readout | |
ACI-35.030 (anti-pTau vaccine) or JACI-35.054 Details Neurological disorder, Alzheimer's disease | Phase 2b Data readout | |
ACI-7104.056 Details Parkinson's disease | Phase 2 Data readout | |
Crenezumab Details Alzheimer's disease, Neurological disorder | Phase 2 Update | |
Semorinemab Details Neurological disorder, Alzheimer's disease | Phase 2 Update | |
ACI-24.060 (anti-Abeta vaccine) Details Neurological disorder, Alzheimer's disease, Down Syndrome | Phase 1/2 Data readout | |
AC1-3024 Details Neurological disorder | Failed Discontinued |